CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal ...

Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic ...

CHICAGO, IL—Five-year follow-up for patients with severe aortic stenosis and low surgical risk affirm the benefits of TAVI with a self-expanding, supra-annular valve compared with surgery, according ...

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement, TAVR, system ...

Evolut Low Risk is a large, prospective trial that initially enrolled 1,478 patients at 86 centers in the United States, Canada, Europe, Japan, Australia and New Zealand to compare the safety and ...

“The delta in favor of Evolut at 2 years is 1.1. The delta in favor of Evolut at 5 years is 2.1. This widening of the curve in favor of TAVR, even though it’s not statistically ...

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...